Trial Profile
A multi-center, double-blind, randomized, placebo-controlled study of orally administered SP01A for 28 days as monotherapy treatment in HIV-infected patients with evidence of resistance to currently available antiretroviral therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Procaine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Samaritan Pharmaceuticals
- 01 Nov 2006 Status change
- 24 Jan 2006 New trial record.